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ABSTRACTSClinicopathologic factors including ER and Her2/neu receptor status are
associated with response to neoadjuvant chemotherapy. The Neoadjuvant
nomogrammay be a useful tool in our population of breast cancer patients.
0920: BREAST RADIO-GUIDED OCCULT LESION LOCALISATION (ROLL):
A GOOD ALTERNATIVE TO WIRE-GUIDED LOCALISATION
Han-Sian Lee, Syeda Gilani, Noaman Sarfraz. Warrington & Halton NHS
Hospitals Trust, Merseyside, UK
Aim: To assess the emerging role of radio-guided occult lesion localisation
(ROLL) as a superior alternative to conventional wire-guided localisation
methods in the removal of impalpable breast lesions. This project assessed
the excision margins and re-excision rates of ROLL and compared them to
NICE-based wide local excision (WLE) standards.
Method: Data was collected on a retrospective basis for all patients who
underwent the ROLL-guided removal of screen-detected and incidental
non-palpable breast cancers from July 2009 to July 2011. Benign tumours
and lymphoma(s) excised using ROLL were excluded.
Results: A total of 76 cases were examined. The re-excision rates using the
ROLL technique with a < 2 mm excision margin stood at 7 cases (9.2%)
overall, but this included 4 patients (5.2%) with multi-focal disease
undergoing mastectomy. Only 3 patients (3.9%) required further WLE as
the only procedure. This is well below the NICE guidelines of re-excision
rates for WLE of 13 - 19% of similar margins.
57% of patients had the tumour size up-scaled from the ultrasonic
measurement on ﬁnal histology.
Conclusion: The ROLL technique for the management of non-palpable
breast lesions does effectively show better results as compared to wire-
guided procedures. Further research is necessary to establish the exact role
of ROLL.
0981: WHEN SHOULD WE CONSIDER CONTRALATERAL PROPHYLACTIC
MASTECTOMY IN BRCA1/BRCA2 NEGATIVE FAMILIAL BREAST CANCER
PATIENTS? A STUDY OF HISTOPATHOLOGICAL PATTERNS
Fatima Aloraiﬁ, Trudi McDevitt, Nuala Cody, Marie Meany, Cliona de
Baroid, Rosemarie Kelly, Adrian Bracken, Andrew Green, James
Geraghty. National Centre for Medical Genetics, Dublin, Ireland
Aims: Little is known on the management of BRCA1/BRCA2-negative
familial breast cancer. This study aims to characterize histopathological
data on these patients in order to help in predicting the likelihood of
contralateral breast cancer.
Methods: A 5-year retrospective study was performed on patients referred
to the National Centre for Medical Genetics in Ireland from 2007-2011 for
genetic testing. Clinical and histopathological reports were collected from
high-risk patients (Manchester score >¼16) negative to BRCA1/BRCA2
(N¼179).
Results:42/179 (23%) high-riskBRCA1/BRCA2-negative patients hadbilateral
breast cancer. 22/42 (52%) were moderate to high grade, 20/42 (47%) were
ER+, 6/42 (14%) were HER2+ and 4/42 (10%) were triple negative. Interest-
ingly, only 7/42 (16%) of these tumours were lobular carcinoma.
Conclusion: BRCA1/BRCA2-positive breast cancer patients are considered
high-risk and offered bilateral prophylactic mastectomies. However, these
patients only account for a small proportion of familial breast cancer.
Despite intensive efforts, the discovery of additional breast cancer pre-
disposing genes to account for the large proportion of familial breast
cancer has so far been unsuccessful. Therefore, efforts should be made to
create a scoring system to predict the likelihood of bilateral breast cancer
in this patient group through histopathological data in a larger scale
multinational study.
0992: COULD A PROPORTION OF FAMILIAL BREAST CANCER PATIENTS
TESTING NEGATIVE TO BRCA1 AND BRCA2 IN FACT BE FALSE
NEGATIVES IN THE REPUBLIC OF IRELAND?
Fatima Aloraiﬁ, Trudi McDevitt, Nuala Cody, Marie Meanie, Cliona de
Baroid, Rosemarie Kelly, Adrian Bracken, Andrew Green, James
Geraghty. National Centre for Medical Genetics, Dublin, Ireland
Aim: The National Centre for Medical Genetics (NCMG) provides genetic
testing for familial breast cancer patients throughout Ireland. We per-
formed an audit of BRCA1/BRCA2-negative familial breast cancer patients
and assessed their characteristics.Methods: BRCA1/BRCA2 genetic testing data was collected prospectively
since the NCMG service was ﬁrst introduced in 1998 to present. In addi-
tion, we collected histopathological data on patients from 2007 to 2011
and performed a literature review on BRCA1/BRCA2-positive breast cancer
histological data from previous international reports to compare it with
our Irish cohort.
Results: Since 1998, 618 high-risk affected breast cancer patients were
referred to the NCMG. Only 16% tested positive for BRCA1/BRCA2 germline
mutations. According to the literature, BRCA1-positive tumours tend to be
triple negative and of high grade. In 179 affected patients negative to
BRCA1/BRCA2, 26/179 (15%) were triple negative, 41/179 (23%) were high
grade and 10/179 (6%) were both.
Conclusion: International statistics show that the susceptibility genes
BRCA1 and BRCA2 comprise 25% of familial breast cancer. However, in
Ireland, we show that only 16% are tested positive for BRCA1/BRCA2
mutations at the NCMG. Our next step will be to perform next generation
DNA sequencing on invited participants in order to address this clinically
important question.
1018: ROLE OF MRI IN INVASIVE BREAST CANCER
D. Oweis, P. Rushton, V. Kurup. North Tees and Hartlepool NHS Foundation
Trust, Stockton, UK
Aim: To study the effect of preoperative breast MRI on change of surgical
management in invasive breast cancers.
Methods: Retrospective study of patients(pts) with invasive breast cancer
who underwent a preoperative breast MRI between Jan ‘09 and Dec’11.
Data collected included demographics, radiological investigations, surgical
treatment &histology.
Results: 79pts. with a mean age of 58.6years were included. 24 pts.
underwent breast conservative surgery, 55 pts. had mastectomy. Mean
histological tumour size was 32.5mm. There was a signiﬁcant difference
between MRI size of tumour (mean 36.5mm) and the histological size
(mean 31.3mm) (p¼ 0.19). A signiﬁcant difference was found between the
mammogram(MMG)/Ultrasound(US) size (mean 19.7mm) and the MRI
size (mean 34.5mm). 31.2% had 2cm discrepancy between MMG/US and
MRI and 56.2% had 1cm, 29.2% were multifocal. Discrepancy of 2cm
between MRI and histology was seen in 19.2% and 1cm in 24.4%, 55.9%
were multifocal.
31pts (39.2%) had a change in the operative plan because of a new ipsi-
lateral multifocality (16pts.), contralateral cancer (1pt) or larger cancer
(12pts). Two pts had both a new multifocality and a contralateral breast
cancer. 84% of those had lobular breast cancer.
Conclusion: MRI plays a major role in detecting additional cancer-
s/bigger size and in planning course of treatment especially in lobular
cancers.
1052: WHAT IS THE COST-EFFECTIVENESS FOR MAMMOGRAMS FOR
DETECTING BREAST CANCER RECURRENCE COMPARED WITH THOSE
FOR BREAST CANCER SCREENING?
Lydia Gabriel, Ellena Smith, Sunreet Randhawa, Katy Hogben. Imperial
College NHS Trust, London, UK
Background: There are limited NICE guidelines regarding follow-up
after breast cancer surgery. At Charing Cross, London patients are fol-
lowed up with yearly clinical and mammographic assessment for
5years. The aim of this audit is to determine if annual mammographic
follow-up for breast cancer is cost effective compared to screening
mammography.
Methods: A retrospective audit, for breast patients cancer undergoing
surgery during 2005 at Charing Cross Hospital, London. Data collected
included operative procedures performed, length of follow-up, and
recurrence (method of detection for recurrence) and survival rates. Data
was compared to the pick-up rate NHS Breast Screening Pro-
gramme(NHSBCSP) Audit2008-2009.
Results: 269patients underwent surgery from January-December 2005,
full data collection was possible on 213patients. Average follow up was
4.68years, which equates to 996mammograms(£34860). During this time
there have been 25deaths and 28recurrences. Of the recurrences, 5were
detected by follow up mammogram only. The NHSBCSP detected 17,045
cancers from2008-2009. 199 follow-up mammograms(costing £6965)
